The effectiveness of the different angiotensin-converting enzyme (ACE) inhibitors in the
treatment of patients with congestive heart failure (CHF) was compared by performing a …

Background Angiotensin-converting enzyme (ACE) inhibitors are established as first-line
therapy in chronic heart failure (CHF). However, conflicting results exist regarding the dose …

Angiotensin converting enzyme (ACE) inhibitors have emerged as a significant advance in
the treatment of heart failure; yet only a minority (ie, 30% to 40%) of eligible patients are …

The renin-angiotension system is activated in many patients with congestive heart failure
(CHF), resulting in angiotensin-mediated vasoconstriction and aldosterone-mediated …

Background. Patients with congestive heart failure have a high mortality rate and are also
hospitalized frequently. We studied the effect of an angiotensin-converting–enzyme inhibitor …

Objectives: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was
performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the …

Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …

The effect on renal function of long-term treatment with either enalapril (n= 123) or placebo
(n= 120) in addition to conventional therapy was studied in a randomized trial in patients …

Heart failure is a common and costly medical condition. Ischemic heart disease and
hypertension account for most cases of heart failure in developed countries. Estimates of the …

Background: The efficacy of ACE‐inhibitor therapy is well documented in the treatment of
chronic heart failure. As pharmacological mechanisms of ACE‐inhibition and angiotensin II …